NoPro - Norwegian Hernia Prophylaxis Study
Launched by SYKEHUSET INNLANDET HF · Feb 28, 2025
Trial Information
Current as of June 04, 2025
Recruiting
Keywords
ClinConnect Summary
The NoPro study is a clinical trial designed to learn more about preventing incisional hernias, which can occur after surgery involving a midline incision in the abdomen. Researchers are comparing two methods of closing the incision: one using a small-bite suture technique alone, and the other using the same technique but with an additional layer of protective mesh. The main goal is to see how many patients develop an incisional hernia within one year after their surgery.
You may be eligible to participate in this trial if you are at least 18 years old and are scheduled for surgery that involves a midline incision with delayed closure. It’s important to note that the study is open to all genders, and participants must provide written consent. If you join the study, you’ll be randomly assigned to one of the two closing methods, and researchers will monitor your recovery and any complications over the year. This research could help improve surgical care and quality of life for future patients undergoing similar procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Surgery predominantly done my midline laparotomy
- • Age 18 years old or older
- • Written consent by patient/family
- • Midline laparotomy with delayed closure
- • No exclusion criteria
- Exclusion Criteria:
- • Age under 18 years
- • Pregnancy
- • Previous abdominal midline hernia mesh repair
- • Abdominal compartment syndrome
- • Linea alba closure not possible
- • Life expectancy under six months
- • Hernia in the midline with transverse diameter lager than 2 cm
About Sykehuset Innlandet Hf
Sykehuset Innlandet HF is a prominent healthcare provider in Norway, dedicated to delivering high-quality medical services and advancing clinical research. As a key player in the region's healthcare landscape, the organization operates several hospitals and specialized units, focusing on a wide range of medical disciplines. Sykehuset Innlandet HF is committed to fostering innovative clinical trials that enhance patient care and contribute to the development of new therapies. With a strong emphasis on collaboration and ethical standards, the organization seeks to improve health outcomes through rigorous research and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamar, , Norway
Patients applied
Trial Officials
Lars Martin Rekkedal, MD BBA
Study Chair
Chief of surgery Hamar Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported